# Infusion of Apomorphine: Long-term Safety Study

> **NCT02339064** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals** · enrollment: 99 (actual)

## Conditions studied

- Idiopathic Parkinson's Disease

## Interventions

- **DRUG:** apomorphine infusion

## Key facts

- **NCT ID:** NCT02339064
- **Lead sponsor:** MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-02
- **Primary completion:** 2018-12
- **Final completion:** 2025-12
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02339064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02339064, "Infusion of Apomorphine: Long-term Safety Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02339064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*